Abstract
We agree with John T Connelly and colleagues that assessment of analyte stability and matrix effects must be part of every assay validation. It is, however, essential that validation is done with the assay under consideration, as different lipoarabinomannan (LAM) assays use different reagents that bind to different LAM epitopes with different stabilities or availabilities.
Key Data
-
Publication Date01 January 2020
-
Primary AuthorTobias Broger
-
SourceThe Lancet
-
LanguageEnglish
Click below to visit original source: